Option Care Health, Inc. Common Stock
OPCH
$21.23
+2.26%
Option Care Health, Inc. is a leading provider of home and alternate-site infusion services, offering treatment for complex conditions such as bleeding disorders, neurological disorders, heart failure, and chronic inflammatory disorders within the healthcare sector. The company is a significant player in the outsourced infusion services market, distinguished by its national scale and focus on cost-effective, patient-preferred care settings outside of hospitals. The current investor narrative is dominated by a significant stock price decline, raising questions about underlying business performance, potential competitive pressures, or reimbursement headwinds in its core infusion services segment, which demands scrutiny of its fundamentals against the market's bearish sentiment.…
OPCH
Option Care Health, Inc. Common Stock
$21.23
Investment Opinion: Should I buy OPCH Today?
Rating: Hold. The core thesis is that OPCH presents a high-risk, high-reward opportunity where the potential for a massive earnings rebound is priced at a reasonable forward multiple, but the catastrophic technical damage and margin profile demand a cautious approach until execution is proven.
Supporting evidence includes the compelling forward P/E of 10.1x, which is inexpensive if the $2.76 EPS estimate is achieved. The stock trades at a deep discount to its 52-week high of $36.8, and its P/S of 0.91x suggests the market is assigning little value to its $7.7B revenue base. However, this is counterbalanced by a trailing P/E of 24.9x on weak current earnings, a gross margin of only 18.06%, and a severe -37.55% 6-month price decline that signals deep fundamental concerns.
The thesis would upgrade to a Buy if the company demonstrates progress toward the $2.76 EPS target in upcoming quarters, stabilizes gross margins above 20%, and the stock sustains a break above the recent June high of $21.38. It would downgrade to a Sell if forward EPS estimates are materially cut, margins contract further, or the stock breaks decisively below the $18.01 support level. Based on the current data, the stock appears fairly valued for the risk, trading at a discount to its own troubled history but not necessarily to its uncertain future.
Sign up to view all
OPCH 12-Month Price Forecast
OPCH is a classic 'show me' story. The valuation is compelling if the analyst forecasts prove correct, but the stock's violent decline and thin margins warrant extreme caution. The investment is a bet on management's ability to engineer a dramatic profit expansion in a low-margin business. The stance is neutral due to the high binary outcome risk; confidence is medium as the key data points are clear but the forward execution is unproven. The stance would upgrade to bullish on confirmation of margin expansion and EPS progress, or downgrade to bearish on a breakdown below $18 support and cuts to forward estimates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Option Care Health, Inc. Common Stock's 12-month outlook, with a consensus price target around $27.60 and implied upside of +30.0% versus the current price.
Average Target
$27.60
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$17 - $28
Analyst target range
Consensus sentiment is based on coverage from 7 analysts, with an average estimated EPS of $2.76 for the coming year, indicating expectations for a dramatic earnings rebound from the current trailing EPS of $0.04. The estimated revenue range is tight, from $7.63 billion to $7.79 billion around an average of $7.70 billion, suggesting analysts have high conviction in the near-term revenue trajectory despite the stock's severe price weakness. Insufficient data is available regarding analyst buy/sell/hold ratings, a consensus price target, or a target price range, which limits the interpretation of forward-looking sentiment; this lack of explicit price targets may indicate that coverage is focused on fundamentals rather than near-term price action, or that targets are in flux following the stock's precipitous decline.
Bulls vs Bears: OPCH Investment Factors
The evidence currently tilts bearish, as the stock's severe price collapse, thin margins, and high short interest reflect tangible fundamental concerns that outweigh the potential valuation opportunity. The most critical tension in the investment debate is the market's skepticism versus analyst optimism regarding the projected earnings leap from $0.04 to $2.76. If the company can deliver on these aggressive EPS forecasts, the current forward P/E of 10.1x would be compellingly cheap. However, if reimbursement pressures, competitive dynamics, or execution issues prevent this profit recovery, the stock's low absolute valuation multiples (P/S of 0.91x) could prove to be a value trap rather than a discount.
Bullish
- Extreme Valuation Discount: The stock trades at a forward P/E of 10.1x, which is a significant discount to its trailing P/E of 24.9x and implies a dramatic earnings recovery is priced in. With a P/S ratio of 0.91x and EV/Sales of 0.77x, the valuation appears low on an absolute basis, potentially pricing in excessive pessimism.
- Strong Analyst EPS Growth Forecast: Analysts project forward EPS of $2.76, representing a massive increase from the trailing EPS of $0.04. This projected 68x earnings growth is the central pillar of the bull case, suggesting the market is severely mispricing the company's near-term profit potential.
- Conservative, Debt-Free Balance Sheet: The reported debt-to-equity ratio of 0 indicates a conservatively financed company with no financial leverage, providing resilience during downturns. A current ratio of 1.53 further confirms adequate short-term liquidity to navigate operational challenges.
- Deeply Oversold Technical Condition: Trading at $20.76, the stock is only 15% above its 52-week low of $18.01 after a -34.86% one-year decline. This extreme oversold condition, coupled with a low beta of 0.65, suggests the sell-off is company-specific and may have created a contrarian entry point.
Bearish
- Severe Profitability and Margin Pressure: The company exhibits thin profitability with a net margin of 3.67% and a gross margin of only 18.06%. For a capital-intensive service business, these low margins leave little room for error and suggest significant operational or reimbursement cost pressures.
- Catastrophic Stock Price and Momentum Collapse: The stock has dramatically underperformed, with a -37.55% 6-month return versus the SPY's +8.8% gain. A 3-month loss of -29.12% indicates persistent negative momentum, and the recent 1-month bounce of 4.95% is weak within the context of a -46.65% max drawdown.
- High Trailing P/E Despite Weak Earnings: A trailing P/E of 24.9x is exceptionally high for a company with an EPS of just $0.04, indicating the market had previously priced in perfection. The gap to the forward P/E of 10.1x shows the market now demands proof of the massive earnings rebound.
- Elevated Short Interest Signaling Skepticism: A short ratio of 2.49 indicates significant bearish sentiment and skepticism in the market regarding the company's ability to execute its turnaround. This creates a potential overhang and risk of a short squeeze if results disappoint.
OPCH Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -34.86% and a 6-month decline of -37.55%, significantly underperforming the SPY's 22.86% gain over the past year. Trading at a current price of $20.76, it sits just 15% above its 52-week low of $18.01, positioning it in deeply oversold territory which may represent a value opportunity but also signals severe negative momentum and potential fundamental concerns. Recent short-term momentum shows a modest 1-month gain of 4.95%, which conflicts sharply with the persistent 3-month loss of -29.12%, suggesting this uptick may be a dead-cat bounce or temporary mean reversion within a broader bear market rather than a convincing trend reversal. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $36.8 and critical support at the $18.01 low; a breakdown below support could trigger another leg down, while a sustained move above the recent June high near $21.38 is needed to suggest stabilization. The stock's beta of 0.654 indicates it has been 35% less volatile than the market, which is unusual given its steep decline and suggests the sell-off has been driven by idiosyncratic, company-specific factors rather than broad market risk.
Beta
0.65
0.65x market volatility
Max Drawdown
-46.6%
Largest decline past year
52-Week Range
$18-$37
Price range past year
Annual Return
-32.8%
Cumulative gain past year
| Period | OPCH Return | S&P 500 |
|---|---|---|
| 1m | +8.8% | +2.1% |
| 3m | -28.6% | +12.5% |
| 6m | -35.6% | +12.4% |
| 1y | -32.8% | +26.4% |
| ytd | -34.2% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OPCH Fundamental Analysis
Revenue trajectory analysis is constrained as specific quarterly revenue and growth rate data are not available in the provided dataset; however, analyst estimates for the coming year project revenue of approximately $7.7 billion, which provides a forward-looking benchmark for the company's scale. The company is profitable, reporting a net income margin of 3.67% and a trailing EPS of $0.04, but profitability appears thin with a gross margin of 18.06% and an operating margin of 5.98%, which are critical for a capital-intensive service business. The balance sheet and cash flow health assessment is limited due to missing specific debt, cash flow, and ROE figures; however, the provided current ratio of 1.53 indicates adequate short-term liquidity, and the debt-to-equity ratio is listed as 0, which, if accurate, would imply a conservatively financed balance sheet with no financial leverage, though this requires verification against detailed financial statements.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OPCH Overvalued?
Given the positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 24.9x, which is substantially higher than the forward PE of 10.1x; this wide gap implies the market expects a significant earnings recovery, with forward estimates embedding an EPS of approximately $2.76 versus a trailing EPS of just $0.04. Peer comparison is challenging as industry average multiples are not provided in the dataset; however, the Price-to-Sales ratio of 0.91x and EV/Sales of 0.77x appear low on an absolute basis, potentially suggesting the market is assigning a discount due to the company's low margin profile or growth concerns. Historical context for the valuation cannot be established as historical ratio data (e.g., its own historical PE range) is not available, limiting the ability to judge whether the current multiple represents a cyclical low or high relative to the company's own past.
PE
24.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the company's razor-thin profitability. A gross margin of 18.06% and net margin of 3.67% in the capital-intensive infusion services business indicate high sensitivity to cost inflation and reimbursement rate changes. The projected earnings rebound (EPS from $0.04 to $2.76) is a binary risk; failure to achieve it would invalidate the forward P/E thesis and likely trigger further multiple compression. The lack of detailed cash flow and debt data, aside from a reported D/E of 0, obscures the true quality of earnings and cash generation.
Market & Competitive Risks are highlighted by the stock's severe underperformance (-57.7 relative strength vs. SPY over 1 year) despite a low beta of 0.65, confirming the sell-off is driven by idiosyncratic, company-specific factors rather than market volatility. These factors likely include competitive pressures in the outsourced infusion market or regulatory/reimbursement headwinds. Trading at a forward P/E of 10.1x, the valuation appears to already discount significant challenges, but further compression is possible if sector multiples contract or if the company's growth profile is re-rated downward by the market.
The Worst-Case Scenario involves a failure to achieve the analyst-projected earnings recovery, coupled with a continuation of margin pressure. This could lead to a re-rating to a distressed valuation, pushing the stock toward and potentially through its 52-week low of $18.01. Given the -46.65% max drawdown already experienced, a realistic adverse scenario could see the stock decline another 15-20% from the current $20.76, resulting in a total loss of approximately -35% to -40% from the recent trading range, landing in the $12-$15 zone if fundamental deterioration is severe.
FAQ
The key risks are, in order of severity: 1) Execution Risk: Failure to achieve the projected EPS of $2.76, which is the foundation of the valuation thesis. 2) Margin Risk: Gross margin of 18.06% is vulnerable to cost inflation and reimbursement cuts, threatening profitability. 3) Momentum Risk: The stock is in a severe downtrend with a -46.65% max drawdown, which can become self-reinforcing. 4) Sentiment Risk: High short interest (short ratio 2.49) reflects bearish conviction that could pressure the stock further on any bad news.
The 12-month forecast is bifurcated with a 50% probability for a base case target of $22-$26, a 30% chance for a bull case reaching $32-$36, and a 20% chance for a bear case falling to $16-$19. The base case, which is most likely, assumes partial progress on the earnings recovery but not a full achievement of the $2.76 EPS estimate, leading to a volatile, range-bound recovery. The forecast hinges almost entirely on the company's ability to translate its $7.7B revenue base into substantially higher profits.
OPCH sends mixed valuation signals. It appears undervalued on a forward basis, with a P/E of 10.1x and P/S of 0.91x, which are low absolute multiples. However, it looks overvalued on a trailing basis with a P/E of 24.9x on earnings of just $0.04 per share. The market is pricing in a steep earnings recovery. Therefore, the stock is fairly valued for the substantial risk it carries; it is neither clearly cheap nor expensive, but rather priced for a specific, optimistic outcome that must be delivered.
OPCH is a high-risk, high-potential reward stock that may be suitable for speculative investors with a long time horizon. The forward P/E of 10.1x is attractive if the company hits its $2.76 EPS target, implying significant upside from the current $20.76 price. However, it is not a 'good buy' for conservative investors, given its -34.86% one-year decline, thin 3.67% net margin, and high short ratio of 2.49 indicating market skepticism. A purchase is a bet on a successful earnings turnaround that is far from guaranteed.
OPCH is unsuitable for short-term trading due to its low beta (0.65) but high idiosyncratic volatility and lack of near-term positive catalysts. It is a long-term, event-driven investment where the horizon is defined by the time needed to confirm or deny the earnings turnaround thesis—likely 2-3 earnings cycles (12-18 months). The stock does not pay a dividend, so total return depends entirely on price appreciation from improved fundamentals. Investors should be prepared to hold for at least 12-18 months to allow the investment thesis to play out.